HIMS stock Q1 earnings loss rattled investors on Monday as Hims & Hers Health reported first-quarter results that combined solid revenue growth with a dramatic swing to unprofitability. The stock closed regular trading at $29.14, up 3.08% on the day. However, the mood shifted fast after the earnings release hit. Shares fell 9.75% in after-hours trading to $26.30. The market’s reaction was clear revenue progress alone was not enough to offset the scale of the loss and the margin deterioration that accompanied it.
What the HIMS stock Q1 earnings loss actually showed
Hims & Hers brought in $608.1 million in first-quarter revenue. That figure represents a 4% increase over the $586 million the company generated in the same quarter last year. On the surface, that looks like progress. Nevertheless, the bottom line told a very different story.
The company recorded a net loss of $92.1 million for the quarter. That is a sharp contrast to the net income of $49.5 million it posted in the same period a year ago. In other words, the business went from profitable to deeply in the red in 12 months. Furthermore, adjusted EBITDA dropped to $44.3 million from $91.1 million in the prior year period a decline of more than 50%.
Gross margin also compressed significantly. It fell to 65% from 73% in the year-ago quarter. That deterioration reflected higher operational costs tied to the company’s expanding healthcare delivery model. As a result, the quality of earnings weakened even as the top line grew.
Subscriber growth masks monetization challenges
One area of genuine progress was subscriber growth. Hims & Hers ended the quarter serving nearly 2.6 million subscribers. That is a 9% increase from the 2.37 million subscribers on its books in the same quarter last year. The growing user base gives the platform greater scale and a wider foundation for delivering personalized healthcare services.
However, the company is earning less from each of those subscribers than it used to. Average monthly revenue per subscriber fell to $80 from $85 a 6% decline. That drop partially cancelled out the benefit of having more subscribers. In short, the platform is reaching more people but extracting less value from each relationship.
The geographic split also revealed a notable shift. Domestic revenue contracted 8% to $529.9 million. At the same time, international revenue surged from just $7.3 million to $78.2 million. That overseas momentum helped cushion the domestic softness, but the reversal in the home market is a trend investors will watch closely in the quarters ahead.
What management is projecting for the rest of 2026
Despite the after-hours selloff, management struck an optimistic tone about the remainder of the year. For the second quarter, the company guided for revenue of $680 million to $700 million. Adjusted EBITDA is expected to land between $35 million and $55 million, implying a margin of roughly 5% to 8%.
For the full fiscal year 2026, the company forecast revenue of $2.8 billion to $3.0 billion. Adjusted EBITDA is projected at $275 million to $350 million. Those figures do not include any potential contribution from the pending Eucalyptus acquisition, which could add further scale if it closes.
Growth strategy and what comes next
Hims & Hers is actively expanding its branded GLP-1 medication portfolio and moving into new care verticals as it broadens its healthcare platform. Additionally, management announced a shift from quarterly to annual shareholder communications a move that changes how investors receive updates going forward.
The company’s growth ambitions are clear. It is building a bigger, broader business. However, Monday’s after-hours drop showed that investors remain focused on profitability. Until Hims & Hers demonstrates it can grow revenue and margins together, the HIMS stock Q1 earnings loss story is likely to weigh on sentiment for some time to come.
Note: This article is for informational purposes only and does not constitute investment advice.
Source: MoneyCheck
Leave a Reply